Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25217869 | 0.85 | CRBN (0.64) | CRBNDDB1SIGMAR1CXCR4 | |
| SCHEMBL30817400 | 0.80 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL25822350 | 0.79 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL27293143 | 0.79 | CRBN (0.52) | CRBNDDB1IKZF1 | |
| SCHEMBL21877147 | 0.79 | DDB1 (0.64) | CRBNDDB1SIGMAR1 | |
| SCHEMBL31342607 | 0.79 | DDB1 (0.64) | CRBNDDB1SIGMAR1 | |
| SCHEMBL30643700 | 0.79 | CRBN (0.54) | CRBNDDB1 | |
| SCHEMBL28588984 | 0.78 | CRBN (0.55) | CRBNDDB1IKZF1 | |
| SCHEMBL30831070 | 0.78 | DDB1 (0.60) | CRBNDDB1 | |
| SCHEMBL23915922 | 0.78 | CRBN (0.55) | CRBNDDB1IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |